Detailed financial statements for Shuttle Pharmaceuticals Holdings, Inc. (SHPH): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $3.13, SHPH has negative trailing earnings (P/E not meaningful) and an ROE of -408.33%. Market capitalisation stands at $2M.
Balance sheet quality for SHPH: current ratio of 0.1, net cash position of $101858. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $18739 | $18000 | $54951 | $60834 | $5972 | 0 | 0 | 0 |
| Gross Profit | -$18739 | -$18000 | -$54951 | -$60834 | -$5972 | 0 | 0 | 0 |
| Research & Development | -$836 | $55572 | $161772 | $1.0M | $1.0M | $3.5M | $3.6M | $4.1M |
| Selling, General & Admin | $185987 | $513059 | $347750 | $721184 | $1.3M | $2.4M | $4.1M | $7.9M |
| Operating Expenses | $185151 | $568632 | $454571 | $1.7M | $2.3M | $5.9M | $7.7M | $11.9M |
| Operating Income | -$203890 | -$586630 | -$509522 | -$1.7M | -$2.3M | -$5.9M | -$7.7M | -$11.9M |
| EBITDA | -$183971 | -$577223 | -$711151 | -$1.0M | -$4.3M | -$4.0M | -$7.8M | -$11.4M |
| Interest Expense | $10881 | $30916 | $39630 | $50788 | $670610 | $2.6M | $1.4M | $70828 |
| Pre-tax Income | -$213594 | -$626139 | -$805732 | -$1.2M | -$5.0M | -$6.6M | -$9.1M | -$11.7M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$213594 | -$626139 | -$805732 | -$1.2M | -$5.0M | -$6.6M | -$9.1M | -$11.7M |
| EPS | $-0.16 | $-0.46 | $-0.68 | $-0.95 | $-3.00 | $-4.10 | $-8857.30 | $-71.60 |
| EPS (Diluted) | $-0.16 | $-0.46 | $-0.68 | $-0.95 | $-3.00 | $-4.10 | $-8857.30 | $-71.60 |
| Shares Outstanding (Diluted) | $1.4M | $1.4M | $1.4M | $1.4M | $1.0M | $1.6M | $1.0M | $163792 |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50709 | $352390 | $117153 | $504749 | $8.4M | $2.6M | $1.9M | $334005 |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $2.9M | 0 | 0 |
| Receivables | $49210 | $3825 | $211455 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $102460 | $613957 | $341187 | $509615 | $8.6M | $5.6M | $2.2M | $502911 |
| Property, Plant & Equipment | $18838 | $838 | $196380 | $135546 | $68714 | $358731 | $295373 | $119702 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $9.8M |
| Total Assets | $121298 | $621275 | $544047 | $651641 | $8.7M | $6.0M | $2.5M | $10.5M |
| Accounts Payable | $79104 | $30731 | $516966 | $828313 | $129245 | $283306 | $596600 | $1.5M |
| Short-term Debt | $314377 | $400000 | $686441 | $849501 | $685473 | $595999 | $874475 | 0 |
| Total Current Liabilities | $405646 | $593819 | $2.1M | $2.2M | $975676 | $1.0M | $1.5M | $8.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $135089 | 0 | 0 |
| Total Liabilities | $405646 | $593819 | $2.2M | $2.3M | $975676 | $1.9M | $1.8M | $8.2M |
| Retained Earnings | -$1.3M | -$1.9M | -$4.5M | -$5.8M | -$8.9M | -$25.4M | -$34.6M | -$46.3M |
| Total Equity | -$284348 | $27456 | -$1.7M | -$1.6M | $7.7M | $4.1M | $709152 | $2.3M |
| Total Debt | $314377 | $400000 | $874285 | $978877 | $748296 | $1.1M | $1.2M | $232147 |
| Net Debt | $263668 | $47610 | $757132 | $474128 | -$7.7M | -$4.4M | -$746672 | -$101858 |
| Working Capital | -$303186 | $20138 | -$1.8M | -$1.7M | $7.6M | $4.6M | $677148 | -$7.5M |
Cash Flow (10y)
| Year | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$213594 | -$626139 | -$805732 | -$1.2M | -$5.0M | -$6.6M | -$9.1M | -$11.7M |
| Depreciation & Amortization | $18739 | $18000 | $54951 | $60834 | $5972 | $6811 | $5463 | $290107 |
| Stock-based Compensation | 0 | 0 | $459589 | $910067 | $237547 | $181960 | $259744 | $932967 |
| Change in Working Capital | -$9027 | $16647 | $7781 | $519154 | -$462790 | $220634 | $138911 | $540617 |
| Operating Cash Flow | -$202705 | -$566692 | -$26831 | -$300336 | -$2.7M | -$5.6M | -$7.3M | -$9.5M |
| Capital Expenditure | 0 | 0 | -$10818 | 0 | 0 | -$19046 | 0 | $5 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$202705 | -$566692 | -$37649 | -$300336 | -$2.7M | -$5.6M | -$7.3M | -$9.5M |
Growth & Margins (10y)
| Year | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Income Growth (YoY) | -193.1% | -28.7% | -43.0% | -333.6% | -32.0% | -38.7% | -28.2% | |
| EPS Growth (YoY) | -193.6% | -48.4% | -38.2% | -217.5% | -36.7% | -215931.7% | +99.2% | |
| Shares Change (YoY) | +0.0% | +0.0% | +0.0% | -23.8% | +53.7% | -35.1% | -84.1% | |
| FCF Growth (YoY) | -179.6% | +93.4% | -697.7% | -787.8% | -110.0% | -30.8% | -29.4% | |
| Effective Tax Rate | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Per-Share Data (10y)
| Year | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $-0.15 | $-0.42 | $-0.03 | $-0.22 | $-2.58 | $-3.52 | $-7.10 | $-57.89 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $1.4M | $1.4M | $1.4M | $1.4M | $1.0M | $1.6M | $1.0M | $163792 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Profitability
| Return on Equity | -408.33% |
| Return on Invested Capital | -312.04% |
| Return on Assets | -91.63% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 0.30 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -10.78 |
Key Ratios (10y)
| Year | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| P/E | -490191.08 | -166941.43 | -112514.62 | -81439.15 | -1306.67 | -221.95 | -0.02 | -0.25 |
| P/B | -367721.53 | 3808307.13 | -61859.51 | -64221.38 | 528.48 | 356.90 | 312.65 | 1.31 |
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Related companies: AKAN · BBLG · BIVI · HSCS · IMCC · ISPC · MSPR
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of SHPH: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks